SYNthesis BioVentures
Overview
SYNthesis BioVentures is a venture capital fund that invests in early-stage therapeutics, including small molecule therapeutics, biologics, and cell and gene therapies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Skin2Neuron | Oct 2024 | VC Round | Lead |
| Aculeus Therapeutics | Sep 2023 | SAFE | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is SYNthesis BioVentures based?
SYNthesis BioVentures is headquartered in Parkville, Australia.
When was SYNthesis BioVentures founded?
SYNthesis BioVentures was founded in 2022.
How many portfolio companies does SYNthesis BioVentures have?
SYNthesis BioVentures has 2 portfolio companies in Caplight's dataset.
What are some companies in SYNthesis BioVentures's portfolio?
Portfolio companies visible on Caplight include Skin2Neuron, Aculeus Therapeutics.
What was SYNthesis BioVentures's most recent investment shown here?
SYNthesis BioVentures's most recent investment in this portfolio sample was in Skin2Neuron in 2024.
What sectors does SYNthesis BioVentures focus on?
SYNthesis BioVentures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does SYNthesis BioVentures focus on?
Stage focus information for SYNthesis BioVentures is not publicly available.
What is SYNthesis BioVentures's AUM?
SYNthesis BioVentures's assets under management are estimated between $16.5M and $49.5M.